We report on the confocal microscopical findings of both corneas of a patient presenting a multiple myeloma associated crystalline keratopathy and the response to treatment. Blurred vision was the first sign of progression of the multiple myeloma. Confocal microscopy images show needle-like structures in the epithelium and stroma of the cornea which regressed after treatment of the multiple myeloma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements.
Curr Treat Options Oncol
January 2025
Tianjin Medical University General Hospital, 154 Anshan Road, Tianjin, 300052, Heping District, China.
According to the guidelines, the primary treatment for multiple myeloma is still based on drugs such as carfilzomib, lenalidomide, or daratumumab. However, patients with relapsed/refractory multiple myeloma (RRMM) may be insensitive or develop resistance to the above therapeutic medications. Thus, formulating standardized and rational treatment regimens for such patients remains an area for consideration.
View Article and Find Full Text PDFBiomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours.
J Cancer Res Clin Oncol
January 2025
Department of Urology, Asklepios Tumorzentrum Hamburg, AK Altona, Hamburg, Germany.
Purpose: microRNA-371a-3p (M371) is considered a highly sensitive and specific serum biomarker of testicular germ cell tumours (GCTs). However, little is known about the expression of M371 in nontesticular malignancies (NTMs), so far. As knowledge about the expression of the marker in other malignancies is a prerequisite for the clinical application of the test we aimed to explore the M371 expression in other cancers.
View Article and Find Full Text PDFFactors and Considerations in No-Treatment Decisions in Patients With Key Hematological Malignancies: A Nationwide, Population-Based Study in the Netherlands.
Eur J Haematol
January 2025
Department of Research & Development, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
Comprehensive insights are lacking into why patients with hematological malignancies (HMs) receive no cancer-directed treatment. We evaluated socio-demographic and cancer-related characteristics, decision-making rationales, and overall survival in patients with three common HMs-diffuse large B-cell lymphoma (DLBCL), symptomatic multiple myeloma (MM), and acute myeloid leukemia (AML)-who do not receive cancer-directed treatment, using the nationwide Netherlands Cancer Registry. A total of 26 945 patients diagnosed with DLBCL (47%), symptomatic MM (29%), or AML (25%) between 2014 and 2021 were included.
View Article and Find Full Text PDFT-cell-based immunotherapies for human immunodeficiency virus patient with relapsed/refractory multiple myeloma: A success story from our clinic.
Br J Haematol
January 2025
Department of Clinical Hematology and Cellular Therapy, Saint Antoine Hospital, APHP, Paris, France.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!